Regression of upper gastric cancer in mice by FHIT gene delivery
- 3 July 2003
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 17 (12), 1768-1770
- https://doi.org/10.1096/fj.03-0241fje
Abstract
Fhit expression is reduced in most cancers, and Fhit replacement by FHIT expression viruses in lung, esophageal, pancreatic, and cervical cancers induces apoptosis in the cancer cells. Mice carrying one or two inactivated Fhit alleles are hypersensitive to development of N-nitrosomethylbenzylamine (NMBA)-induced forestomach tumors. In the present study, we investigated the kinetics and mechanism of tumor reversal and intervention by oral delivery of FHIT expression viruses. Tumor analysis showed that: a) by 37 days post-NMBA, control mice showed approximately 7 tumors and by 84 days approximately 10 tumors/forestomach; b) mice receiving FHIT virus at 2 or 42 days post-NMBA showed significantly reduced tumor burdens; c) Fhit was still expressed at 82 days postinfection; d) control viral infection had no effect on tumor development; and e) reduced Bcl2, increased Bax expression, and increased TUNEL-positive apoptotic nuclei characterized the restored epithelia of FHIT transduced forestomachs. Thus, FHIT viral gene delivery prevents or retards development of carcinogen-induced forestomach tumors and reverses development of established tumors by 60-70% through an apoptotic pathway. This dramatic reduction in tumor burden emphasizes the efficacy of targeting the FHIT apoptotic pathway for tumor eradication.Keywords
Funding Information
- U.S. Public Health Service (CA77738, CA78890, CA56036)
- National Cancer Institute (99B045-REN)
- American Institute for Cancer Research (99B045-REN)
This publication has 10 references indexed in Scilit:
- FRA3B and other common fragile sites: the weakest linksNature Reviews Cancer, 2001
- The tumor spectrum in FHIT- deficient miceProceedings of the National Academy of Sciences of the United States of America, 2001
- Successful Treatment of Primary and Disseminated Human Lung Cancers by Systemic Delivery of Tumor Suppressor Genes Using an Improved Liposome VectorMolecular Therapy, 2001
- FHIT gene therapy prevents tumor development in Fhit-deficient miceProceedings of the National Academy of Sciences of the United States of America, 2001
- Muir–Torre-like syndrome in Fhit-deficient miceProceedings of the National Academy of Sciences of the United States of America, 2000
- An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and EpilepsyScience, 2000
- The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle controlProceedings of the National Academy of Sciences of the United States of America, 1999
- Novel Tools for Production and Purification of Recombinant Adenoassociated Virus VectorsHuman Gene Therapy, 1998
- Peroral gene therapy of lactose intolerance using an adeno-associated virus vectorNature Medicine, 1998
- Replacement of Fhit in cancer cells suppresses tumorigenicityProceedings of the National Academy of Sciences of the United States of America, 1997